BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng S, Zhou J, Li Z, Appelman HD, Zhao L, Zhu J, Wang TD. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma. Colloids Surf B Biointerfaces 2019;184:110498. [PMID: 31536939 DOI: 10.1016/j.colsurfb.2019.110498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kines RC, Schiller JT. Harnessing Human Papillomavirus’ Natural Tropism to Target Tumors. Viruses 2022;14:1656. [DOI: 10.3390/v14081656] [Reference Citation Analysis]
2 Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mintz KJ, Leblanc RM. The use of nanotechnology to combat liver cancer: Progress and perspectives. Biochim Biophys Acta Rev Cancer 2021;1876:188621. [PMID: 34454983 DOI: 10.1016/j.bbcan.2021.188621] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
5 Kang X, Li M, Liu L, Liu S, Hu H, Zhang R, Ning S, Tian Z, Pan Y, Guo X, Wu K. Targeted imaging of esophageal adenocarcinoma with a near-infrared fluorescent peptide. BMC Gastroenterol 2021;21:260. [PMID: 34118882 DOI: 10.1186/s12876-021-01840-3] [Reference Citation Analysis]
6 Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021;11:5464-90. [PMID: 33859758 DOI: 10.7150/thno.54822] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]